PT - JOURNAL ARTICLE AU - Launay, Odile AU - Cachanado, Marine AU - Nguyen, Liem B Luong AU - Ninove, Laetitia AU - Lachâtre, Marie AU - Ben Ghezala, Inès AU - Bardou, Marc AU - Schmidt-Mutter, Catherine AU - Felten, Renaud AU - Lacombe, Karine AU - Surgers, Laure AU - Laine, Fabrice AU - Allain, Jean-Sébastien AU - Botelho-Nevers, Elisabeth AU - Tavolacci, Marie-Pierre AU - Chidiac, Christian AU - Pavese, Patricia AU - Dussol, Bertrand AU - Priet, Stéphane AU - Deplanque, Dominique AU - Touati, Amel AU - Curci, Laureen AU - Konate, Eleine AU - Hamouda, Nadine Ben AU - Besbes, Anissa AU - Nubret, Eunice AU - Capelle, Florence AU - Berard, Laurence AU - Rousseau, Alexandra AU - Tartour, Eric AU - Simon, Tabassome AU - de Lamballerie, Xavier AU - , TI - Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine AID - 10.1101/2022.05.25.22274904 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.25.22274904 4099 - http://medrxiv.org/content/early/2022/05/27/2022.05.25.22274904.short 4100 - http://medrxiv.org/content/early/2022/05/27/2022.05.25.22274904.full AB - Background Variant-adaptated vaccines against coronavirus disease 2019 (COVID-19) as boosters are needed to increase a broader protection against SARS CoV-2 variants. New adjuvanted recombinant protein vaccines as heterologous boosters could maximize the response.Methods In this randomized, single-blinded, multicenter trial, adults who had received two doses of Pfizer-BioNTech mRNA vaccine (BNT162b2) 3 to7 months before were randomly assigned to receive a boost of BNT162b2, Sanofi/GSK SARS-CoV-2 adjuvanted recombinant protein MV D614 (monovalent parental formulation) or SARS-CoV-2 adjuvanted recombinant protein MV B.1.351 vaccine (monovalent Beta formulation). The primary endpoint was the percentage of subjects with a ≥10-fold increase in neutralizing antibody titers for the Wuhan (D614) and B.1.351 (Beta) SARS-CoV-2 viral strains between day 0 and day 15.Findings The percentages of participants whose neutralizing antibody titers against the Wuhan (D614) SARS-CoV-2 strain increased by a factor ≥10 between day 0 and day 15 was 55.3% (95% CI 43.4-66.7) in MV D614 group (n=76), 76.1% (64.5-85.4) in MV B.1.351 (Beta) group (n=71) and 63.2% (51.3-73.9) in BNT162b2 group (n=76). These percentages were 44.7% (33.3-56.6), 84.5% (74.0-92.0) and 51.3% (39.6-63.0) for the B.1.351 (Beta) viral strain, respectively. Higher neutralizing antibodies rates against Delta and Omicron BA.1 variants were also elicited after Sanofi/GSK MV Beta vaccine compared to the other vaccines. Comparable reactogenicity profile was observed with the three vaccines.Interpretation Heterologous boosting with the Sanofi/GSK Beta formulation vaccine resulted in a higher neutralizing antibody response against Beta variant but also the original strain and Delta and Omicron BA.1 variants, compared with mRNA BNT162b2 vaccine or the Sanofi/GSK MVD614 formulation. New vaccines containing Beta spike protein may represent an interesting strategy for broader protection against SARS CoV-2 variants.Funding French Ministries of Solidarity and Health and Research and SanofiTrial registration number ClinicalTrials.gov identifier NCT05124171; EudraCT identifier 2021-004550-33.Competing Interest StatementOdile Launay - AstraZeneca (Financial) - GlaxoSmithKline (Advisor/Consultant, Grant/Research Support) - Johnson & Johnson (Advisor/Consultant, Grant/Research Support) - MD (Advisor/Consultant) - Moderna (Advisor/Consultant) - MSD (Data safety monitoring board) - Pfizer (Advisor/Consultant, Grant/Research Support) - Sanofi Pasteur (Advisor/Consultant, Grant/Research Support, Data safety monitoring board) Tabassome Simone: -DGOS (French Ministry of health), Astrazeneca, Bayer, Novartis, Sanofi, Boehringer, Daiichi Sankyo, Eli Lilly, GSK: grant -Astrazeneca, Sanofi, Bayer, Ablative Solutions and 4 Living Biotech: personal fees for boardmembership and consulting Karine Lacombe: - Gilead, MSD, Janssen, ViiV, Spikimm (fees and Grant/Research Support) -Janssen, Gilead, MSD, Sobi, and Chiesi (fees for development of educational presentations). Elisabeth Botelho-Nevers -Sanofi Pasteur (grant pending from) - Pfizer and Janssen (fees for board membership) Liem Binh Luong Nguyen: Pfizer (personal fees for advisory experts and participation to conference). Xavier De Lamballerie/ -INSERM (research grant). Clinical TrialNCT05124171Funding StatementThis study was funded by the French Ministry of Solidarity and Health and SanofiAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee/IRB of Comite de Protection des Personnes Ile de France III and the French Health Products Safety Agency gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript